Insider Deal: OPKO Health, Inc. (OPK)’s CEO & Chairman Phillip Frost Acquired 30,000 shares; EUROFINS SCIENTIFIC SA ORDINARY SHARES (ERFSF) SI Increased By 5.59%

Eurofins Scientific SE (OTCMKTS:ERFSF) Logo

EUROFINS SCIENTIFIC SA ORDINARY SHARES (OTCMKTS:ERFSF) had an increase of 5.59% in short interest. ERFSF’s SI was 34,000 shares in June as released by FINRA. Its up 5.59% from 32,200 shares previously. With 200 avg volume, 170 days are for EUROFINS SCIENTIFIC SA ORDINARY SHARES (OTCMKTS:ERFSF)’s short sellers to cover ERFSF’s short positions. The SI to EUROFINS SCIENTIFIC SA ORDINARY SHARES’s float is 0.31%. It closed at $516.21 lastly. It is down 0.00% since June 7, 2017 and is . It has underperformed by 12.57% the S&P500.

Eurofins Scientific SE provides various analytical testing services worldwide. The company has market cap of $9.07 billion. It offers a portfolio of approximately 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products. It has a 42.11 P/E ratio. The firm provides food and feed testing, biopharma, genomic, agroscience, agro testing, consumer product testing, environment testing, clinical diagnostics, environment testing, forensic, medical device testing, and genomic services, as well as chemicals registration, evaluation, and authorization services.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The company has market cap of $2.28 billion. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. It currently has negative earnings. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.

As disclosed in a legal form filed with the SEC on June 07, 2018, Phillip Frost, CEO & Chairman of Opko Health Inc and a person familiar with the corporation, obtained 30,000 shares of the company for close to $121,500 U.S. Dollars which is based on an average stock price per share of $4.1. In the last month, he also bought 279,900 shares that are worth about $1.07 million USD. Phillip Frost now indirectly owns 188206356 shares. He also directly owns 3068951 shares. In total he holds a stake of 34.19%.

More recent OPKO Health, Inc. (NASDAQ:OPK) news were published by: Nasdaq.com which released: “Here’s Why OPKO Health Dropped as Much as 23% Today” on May 18, 2018. Also Fool.com published the news titled: “Better Buy: Opko Health, Inc. (OPK) vs. Myriad Genetics (MYGN)” on May 18, 2018. Nasdaq.com‘s news article titled: “OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test” with publication date: May 18, 2018 was also an interesting one.

Investors sentiment increased to 1.08 in 2018 Q1. Its up 0.24, from 0.84 in 2017Q4. It increased, as 22 investors sold OPKO Health, Inc. shares while 52 reduced holdings. 23 funds opened positions while 57 raised stakes. 123.26 million shares or 3.45% more from 119.15 million shares in 2017Q4 were reported. Gamco Investors Incorporated Et Al reported 88,800 shares. 848,057 are owned by Rk Asset Mgmt Lc. Weiss Multi accumulated 1.29M shares. Raymond James And Associates reported 400,240 shares. Virtu Fincl Ltd Limited Liability Company stated it has 0.02% in OPKO Health, Inc. (NASDAQ:OPK). Dimensional Fund Advsr L P accumulated 3.58 million shares. Horrell Capital Mgmt holds 0% or 300 shares. Virginia Retirement Et Al owns 40,000 shares or 0% of their US portfolio. Cambridge Inv Research Inc has invested 0.02% in OPKO Health, Inc. (NASDAQ:OPK). Van Eck Corp stated it has 0% in OPKO Health, Inc. (NASDAQ:OPK). Cibc Asset reported 0% in OPKO Health, Inc. (NASDAQ:OPK). Walleye Trading Ltd Liability Co has invested 0% of its portfolio in OPKO Health, Inc. (NASDAQ:OPK). Timber Hill Limited Liability Corporation stated it has 27,640 shares or 0.01% of all its holdings. Goldman Sachs Gru holds 1.76M shares or 0% of its portfolio. Mackay Shields Limited Liability has invested 0.06% of its portfolio in OPKO Health, Inc. (NASDAQ:OPK).

Since January 22, 2018, it had 60 insider purchases, and 0 insider sales for $12.12 million activity. Fishel Robert Scott bought $8,622 worth of stock. FROST PHILLIP MD ET AL had bought 80,000 shares worth $245,868. Rubin Steven D had bought 6,000 shares worth $19,500. $7,011 worth of OPKO Health, Inc. (NASDAQ:OPK) was bought by Logal Adam on Tuesday, March 13.

The stock decreased 1.45% or $0.06 during the last trading session, reaching $4.07. About 2.95 million shares traded. OPKO Health, Inc. (NASDAQ:OPK) has declined 41.73% since June 7, 2017 and is downtrending. It has underperformed by 54.30% the S&P500. Some Historical OPK News: ; 27/04/2018 – OPKO Health: Withdraws Its Request to Voluntarily Delist Its Common Stk From the TASE; 18/05/2018 – OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test; 16/03/2018 OPKO Health Announces Landmark Study Showing 4KscoreĀ® Test is Strong Predictor of Prostate Cancer Mortality Published in Europ; 27/04/2018 – OPKO HEALTH – HAVE SPOKEN WITH CO’S ISRAEL-BASED INVESTORS; THEY EXPRESSED DESIRE CO CONTINUE PRESENCE ON TASE AND URGED CO TO RECONSIDER DECISION; 23/03/2018 – OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes; 08/05/2018 – OPKO HEALTH 1Q LOSS/SHR 8.0C, EST. LOSS/SHR 12.8C; 21/04/2018 – DJ OPKO Health Inc, Inst Holders, 1Q 2018 (OPK); 18/05/2018 – OPKO Said Earlier That Novitas Solutions Proposed Non-Coverage Policy for 4KScore Test for Medicare in Draft Determination; 01/05/2018 – OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories; 08/05/2018 – OPKO HEALTH 1Q REV. $254.9M, EST. $237.0M

Analysts await OPKO Health, Inc. (NASDAQ:OPK) to report earnings on August, 14. They expect $-0.07 EPS, down 75.00% or $0.03 from last year’s $-0.04 per share. After $-0.08 actual EPS reported by OPKO Health, Inc. for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

OPKO Health, Inc. (NASDAQ:OPK) Institutional Positions Chart